Spinal muscular atrophy (SMA): investigational treatments
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Spinal muscular atrophy (SMA): investigational treatments. Phenylbutyrate, Sodium butyrate. Fully referenced neurology checklist.
Histone deacylase (HDAC) inhibitors
- Phenylbutyrate
- Sodium butyrate
- Suberoylanilide hydroxamic acid
- Trichostatin A
- Valproic acid
Other investigational treatments
Locked: subscribe to see this section.
References
- Lorson CL, Rindt H, Shababi M. Spinal muscular atrophy: mechanisms and therapeutic strategies. Hum Mol Genet 2010; 19:R111-R118.
- Sproule DM, Kaufmann P. Therapeutic developments in spinal muscular atrophy. Ther Adv Neurol Disord 2010; 3:173-185.
- Burnett BG, Crawford TO, Sumner CJ. Emerging treatment options for spinal muscular atrophy. Curr Treat Options Neurol 2009; 11:90-101.
- Bertini E, Dessaud E, Mercuri E, et al; Olesoxime SMA Phase 2 Study Investigators. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16:513-522.